Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
复制标题
DOI：
10.1146/annurev-pharmtox-010814-124835
复制
发表时间：
2015
影响因子：
12.5
通讯作者：
Relling MV
中科院分区：
文献类型：
--
作者：
Dunnenberger HM;Crews KR;Hoffman JM;Caudle KE;Broeckel U;Howard SC;Hunkler RJ;Klein TE;Evans WE;Relling MV
虽然药物遗传学领域已经存在了几十年，但药物遗传学检测在临床护理中的实施一直很缓慢。有许多出版物描述了药物遗传学临床实施的障碍。最近，一些免费的，可用的资源已经开发出来，以帮助解决这些障碍。在这篇综述中，我们讨论了目前的程序，使用先发制人的基因分型，以优化药物治疗的病人。基于阵列的抢先检测包括大量影响多种高风险药物的相关药物基因。使用先发制人的方法允许基因分型结果在任何处方决定之前可用，使得基因组变异可以被认为是治疗计划中的固有患者特征。这篇综述描述了已经实施抢先基因分型的项目中的共同要素，并强调了实施的关键过程，包括临床决策支持。
Although the field of pharmacogenetics has existed for decades, the implementation of, pharmacogenetic testing in clinical care has been slow. There are numerous publications, describing the barriers to clinical implementation of pharmacogenetics. Recently, several freely, available resources have been developed to help address these barriers. In this review we, discuss current programs that use preemptive genotyping to optimize the pharmacotherapy of, patients. Array-based preemptive testing includes a large number of relevant pharmacogenes, that impact multiple high-risk drugs. Using a preemptive approach allows genotyping results to, be available prior to any prescribing decision so that genomic variation may be considered as, an inherent patient characteristic in the planning of therapy. This review describes the common, elements among programs that have implemented preemptive genotyping and highlights key, processes for implementation, including clinical decision support.